Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Npc1m1N mutation
(3 available);
any
Npc1 mutation
(72 available)
Npc1tm1.1Apl mutation
(0 available);
any
Npc1 mutation
(72 available)
Tg(GFAP-cre/ERT2)13Kdmc mutation
(1 available)
|
|
|
normal phenotype
|
• mice treated with tamoxifen at 6 weeks of age exhibit normal weight gain, motor performance, and survival and do not show Purkinje cell loss, axonal spheroids, demyelination, or activated astrocytes or microglia in the cerebellum, and no functional alterations in synaptic transmission
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc1a2tm1.1Pros mutation
(1 available);
any
Slc1a2 mutation
(40 available)
Tg(GFAP-cre/ERT2)13Kdmc mutation
(1 available)
|
|
|
mortality/aging
|
• following postnatal tamoxifen treatment (P5-P9), mice die significantly earlier than control mice, with a median survival at 23 weeks of age
|
growth/size/body
|
• tamoxifen-treated mice gain significantly less weight than controls from 10 weeks of age
|
behavior/neurological
N |
• at 28-67 weeks of age, tamoxifen-treated mice show no significant differences in total SHIRPA scores relative to control mice
|
|
• tamoxifen-treated mice show more electroencephalographic seizure events than controls
• however, no spontaneous clinical seizures are observed
|
nervous system
N |
• at 14-19 weeks of age, tamoxifen-treated mice show only a minor, insignificant decrease in the uptake of L-[3H]glutamate (~15%) and D-[3H]aspartate (~13%) into crude forebrain synaptosomes relative to controls
|
|
• tamoxifen-treated mice show more electroencephalographic seizure events than controls
• however, no spontaneous clinical seizures are observed
|
|
• tamoxifen-treated mice show a significantly higher number of automatically detected spike-trains (electroencephalographic seizures) per 20 min of scalp EEG recording relative to controls (18.7 +/- 7.2 vs 1.9 +/- 0.5)
|